


PHARMACEUTICAL 2019

Corvus Pharmaceuticals Inc. Rank 154 of 371





PHARMACEUTICAL 2019

Corvus Pharmaceuticals Inc. Rank 154 of 371

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 332% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is -110%, being 222% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	115,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,027
Liabilities, Non-Current	869
Other Assets	463
Other Compr. Net Income	7.0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,283
Property and Equipment	2,180
Research and Development	38,586
Revenues	0
Selling, General and Administrative Expense	10,636

Output Variable	Value in 1000 USD
Assets	118,232
Liabilities	7,896
Expenses	49,222
Stockholders Equity	110,336
Net Income	-46,939
Comprehensive Net Income	-46,936
Economic Capital Ratio	-110%